中
  • HOME

  • Company

    • GenFleet Overview
    • Vision & Mission
    • Management Team
    • Advisory Board
    • Company History
    • CSR Philosophy
  • Science

    • Our Pipeline
    • Selected Targets
    • R&D Platform
  • Media

    • Press Release
    • Media Coverage
  • Investors

    • Institutional Investors
    • IR Announcements
  • Careers

    • Overview
    • Culture
    • Highlights
    • Benefits
    • Join Us
  • Contact

jinfangLOGOzuhejihekouhao-05.png

HOME

Company

  • GenFleet Overview
  • Vision & Mission
  • Management Team
  • Advisory Board
  • Company History
  • CSR Philosophy

Science

  • Our Pipeline
  • Selected Targets
  • R&D Platform

Media

  • Press Release
  • Media Coverage

Investors

  • Institutional Investors
  • IR Announcements

Careers

  • Overview
  • Culture
  • Highlights
  • Benefits
  • Join Us

Contact

中
Home
Investors
IR Announcements
Jan 01, 2022
GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the completion of $75 million (~500 million RMB) series C financing. This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital

Jan 27, 2021
GenFleet Therapeutics Completes Series B+ Financing

January 27, 2021 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology, today announced the completion of its Series B+ financing worth hundreds of millions in RMB.

Mar 08, 2020
GenFleet Therapeutics Announces Series B Financing to Boost First-in-class Drug Development

March 8, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology, announced to have completed its series B financing led by CDH Investments and Shenzhen Capital Group.

Nov 30, 2018
GenFleet Therapeutics Closes Series A Financing to Advance Clinical Development of Small Molecules for Immuno-Oncology Therapeutics

November 30, 2018 (Shanghai, China) -- GenFleet Therapeutics recently announced the close of its series A financing worth 120 million yuan, which was led by Ally Bridge Group and participated by Sinopharm Capital and CSPC Pharma.

  • 1
jinfangLOGOzuhejihekouhao-08.png
Company
Science
Media
Investors
Careers
Contact
GenFleet Therapeutics (Shanghai)

1206 Zhangjiang Road, Building A, Shanghai

021-6882 1388

201203

GenFleet Therapeutics (Zhejiang)

1 Yunhai Road, Building 3 (Southern Division), Level 4, Shaoxing City, Zhejiang Province

0575-8258 6890

312000

Offical Wechat
qrcode_for_gh_ae7817a32e15_258.jpg
GenFleeter Wechat
jinfangren-121.jpg
Copyright © 2021 GenFleet Therapeutics (Shanghai) Inc  |  沪ICP备18009875号